Showing 6951-6960 of 8649 results for "".
- Ophthalmic OR Microscope Market to See More Than 6 Percent Growth over Next Five Yearshttps://modernod.com/news/ophthalmic-or-microscope-market-to-see-more-than-6-percent-growth-over-next-five-years/2480110/Market Scope expects the global ophthalmic operating room (OR) microscope market to grow at a healthy pace of more than 6 percent over the next 5 years, as 2018 revenues of $403 million climb to nearly $548 million by 2023. Revenues will rise most sharply in Latin America and other develop
- Chinese Researchers Use Waste Corneal Lenses to Treat Eye Diseasehttps://modernod.com/news/chinese-researchers-use-waste-corneal-lenses-to-treat-eye-disease/2480118/Chinese researchers are celebrating a breakthrough in the treatment of eye disease by using “waste” corneal lenses after laser surgery for near- and far-sightedness, according to a report in XinhuaNet. A
- ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149 for Treatment of DMEhttps://modernod.com/news/thrombogenics-enrolls-first-patient-in-phase-1-clinical-study-evaluating-thr-149-for-treatment-of-dme/2480139/ThromboGenics NV announced that it has successfully enrolled the first patient in a phase 1 open-label, multicenter, dose escalation study evaluating the safety of THR-149 in the treatment of DME (NCT03511898). THR-149 is a novel plasma kallikrein inhibitor generated using Bicycle Therapeu
- Diopsys: Study Highlights the Important Role of PERG in Evaluation of Manifest and Suspected Glaucomahttps://modernod.com/news/diopsys-study-highlights-the-important-role-of-perg-in-evaluation-of-manifest-and-suspected-glaucoma/2480170/Pattern electroretinography (PERG) is again revealed as a powerful tool for evaluating patients with early stage glaucoma, particularly glaucoma suspects, according to a news release from Diopsys. According to the latest study published in Current Ophthalmology Reports by Porciatt
- Hoya Achieves CE Mark for 4-in-1 Multisert Preloaded Delivery System with Vivinex IOLhttps://modernod.com/news/hoya-achieves-ce-mark-for-4-in-1-multisert-preloaded-delivery-system-with-vivinex-iol/2480171/Hoya Surgical Optics has obtained European CE Mark for the Vivinex IOL with the new multiSert 4-in-1 preloaded delivery system. MultiSert offers cataract surgeons control in the palm of their hands as they now have the option of using either a two-handed screw or a one-handed technique while impl
- Optos Unveils Monaco Ultra-Widefield Imaging Device with OCT Capabilitieshttps://modernod.com/news/optos-unveils-monaco-ultra-widefield-imaging-device-with-oct-capabilities/2480175/Optos has announced that Monaco, which the company describes as the first ultra-widefield imaging device combined with OCT, was launched Thursday in the United States. Monaco is a compact desk-top UWF retinal imaging device that provides greater imaging functionality and expands the compan
- Camras Vision Announces Completion of $5.7 Million Financing for Novel Glaucoma Devicehttps://modernod.com/news/camras-vision-announces-completion-of-5-7-million-financing-for-novel-glaucoma-device/2480215/Camras Vision has closed on $5.7 million in equity funding to be used to support four clinical trials globally, including a pilot study in the United States, to study the efficacy of the Camras device for the treatment of refractory glaucoma. The funding was made in its
- Exploring a Connection Between GLP-1 Drugs and Vision Losshttps://modernod.com/news/exploring-a-connection-between-glp-1-drugs-and-vision-loss/2484306/Two studies presented at the 2025 AAO Annual Meeting explored a possible connection between GLP-1 drugs and vision loss. Using data from the World Health Organization’s global database of drug safety reports, researchers at the University of Ottawa Eye Institute, University of Tor
- Duke Eye Center Implants Cell-Based Therapy for MacTelhttps://modernod.com/news/duke-eye-center-implants-cell-based-therapy-for-mactel/2484304/Duke Eye Center announced that its team is the first at a US academic medical center to implant a new commercially available cell-based gene therapy for macular telangiectasia type 2 (MacTel). No treatment was available to slow the progression of MacTel until the FDA approved revakinagene taroret
- Viridian Submits BLA for Veligrotug in Thyroid Eye Diseasehttps://modernod.com/news/viridian-submits-bla-for-veligrotug-in-thyroid-eye-disease/2484303/Viridian Therapeutics has submitted a Biologics License Application (BLA) to the FDA for veligrotug, the company’s investigational therapy for thyroid eye disease (TED). The submission, completed in October, follows positive results from two pivotal phase 3 trials, THRIVE and THRIVE-2, that